{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"592","upperLimit":"4158","value":"2070"},{"groupId":"OG001","lowerLimit":"615","upperLimit":"3430","value":"2150"},{"groupId":"OG002","lowerLimit":"1523","upperLimit":"5121","value":"2105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"91"},{"groupId":"OG002","value":"42"}],"units":"Participants"}],"description":"Cyclophosphamide plasma concentration-time data are collected on day 9 in one cycle of induction chemotherapy. Individual estimates of cyclophosphamide AUC0-24h (area under concentration curve from time 0 to 24 hours post-dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during a cycle of induction therapy and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion","title":"Cyclophosphamide AUC0-24h in Induction Chemotherapy","type":"SECONDARY","unitOfMeasure":"µmol·h/L"}